Worldwide Clinical Trials’ Post

At TRiNDS we specialize in advancing research and treatments for those living with rare neuromuscular diseases. TRiNDS is headquartered in Pittsburgh, Pennsylvania with a global presence extending to over 30 countries and 200 sites. Our expertise covers early-stage trials to postmarketing studies, supported by a broad network of rare disease experts who are dedicated to improving patient outcomes. TRiNDS understands the unique challenges that accompany rare disease clinical trials. Our personalized approach allows us to tailor the selected services to meet the specific needs of each project, ensuring the best possible support for our clients and the patients they serve. #ClinicalResearchOrganization #ClinicalTrials #DuchenneAwareness #MuscularDystrophy #MuscularDystrophyResearch #RareDiseaseResearch #ResearchForACure #PatientDrivenResearch

Dr. Sarah Tabrizi shares a message of hope about finding effective therapies targeting the CAG repeat for Huntington’s disease. The partnership between researchers and HD families is what makes these advancements possible. The next few years will bring exciting new clinical trials! #research #cures #HuntingtonsDisease #cureHD #huntingtonsdiseaseawareness #HuntingtonsDiseaseAwarenessMonth

The past year has been an exciting time for the #AlzheimersDisease (AD) community, as new advancements uncover more information about treating the disease. Esteemed neurologists Sharon Cohen, MD, FRCPC, and David Weisman, MD met with Eisai’s Michael Irizarry, MD, MPH, to share their perspectives on AD clinical trial design and what those in the field need to know when evaluating and understanding data outcomes for patients. Read more about their insightful discussion: bit.ly/3IUcHZ4

🔔 Our #healtheconomists Inna Feldman and Filipa Sampaio are part of the PsyPal consortium - the #firstever European grant to fund clinical research into #psychedelic #assisted #therapy. The trial will investigate whether #psilocybintherapy can help ease #psychological and #existential #distress in patients suffering from one of four progressive diseases: chronic obstructive pulmonary disorder (#COPD), multiple sclerosis (#MS), amyotrophic lateral sclerosis (#ALS), and atypical #Parkinson’s disease (#APD). 📑 Learn more about the project here 👉 https://lnkd.in/eSX63rdu and follow PsyPal here 👉 https://lnkd.in/dTm3zRnp

Such an amazing World Symposium on PH #WSPH we had! It was a great opportunity to network and meet friends and colleagues from around the world. Wonderful high-level discussions and some new treatment #opportunities for our patients. My favorite #HotTopic: why do #trials fail in PH associated with chronic lung diseases? 1. Appropriate patient population/phenotype: •Degree of parenchymal vs vascular derangement • Pre-capillary PH vs post-capillary vs combined pre/post capillary PH • Parenchymal diagnosis (ILD vs CPFE, specifically degree of emphysema) 2. Appropriate duration of trial 3. Choice of endpoint: PVR vs 6MWT vs a clinical combination endpoint 4. Choice of medication dose and route of administration We will be waiting for the upcoming publication of task forces recommendations!

🎗️ Today, on Rare Disease Day, let us shed light on #ALS (Amyotrophic Lateral Sclerosis), a condition that affects thousands worldwide. Despite being classified as rare, ALS has a profound impact, with someone being diagnosed every 90 minutes. At 2N Pharma, we are dedicated to advancing research and treatment options for ALS. Our commitment to finding a cure is unwavering, and on this day of awareness, we stand with patients, caregivers, and advocates in the fight against ALS. Together, let us amplify our voices, spread awareness, and support initiatives that bring us closer to a world without ALS. #RareDiseaseDay #RareDisease #ALSawareness #Sjældnedagen 

Out of 150 clinical programs in active development for #Alzheimer's disease, 23 of them are Phase 3. Read our new article to learn more about current treatment options and key significant therapeutic developments based on #IQVIA #PipelineLink: https://bit.ly/3UxzoJA

Today we join the The International Alliance of ALS/MND Associations in celebrating a global day of recognition and awareness for ALS/MND disease.     A progressive neurodegenerative disorder, #ALS leads to loss of muscle movement, eventual paralysis, and can be fatal. At Athira, we are advancing our investigational ALS treatment, ATH-1105, for the potential benefit of the ALS community.   Learn more about ALS and the therapeutic unmet need we strive to fill: https://bit.ly/4aITwgv #ALSMNDWithoutBorders 

Unmet Needs in Rare Diseases: A Call for Action Continuing our Rare Disease Day (Feb 29th) series, ZoomRx delves into unmet needs identified by 100 MDs treating these conditions. Key findings:  ➡️Improved treatment efficacy is the top unmet need, highlighting the crucial need for effective treatments.  ➡️Investment in research for new therapeutic targets and modalities is strongly emphasized by MDs.  ➡️Clinical decision support tools and educational programs are seen as crucial resources for improved care. These findings underscore the need for continued research, collaboration, and targeted resources to address the unique challenges of rare diseases. Read more in detail: https://bit.ly/49S00tm Stay tuned for our next post on patient challenges! #RareDiseaseDay #UnmetNeeds #MedicalResearch #Healthcare 

Sickle Cell Awareness Month is a great opportunity to raise awareness about sickle cell disease, its impact, and the importance of research and support. September is Sickle Cell Awareness Month. Join us in spreading awareness about sickle cell disease, supporting those affected, and advocating for better treatment options. Together, we can make a difference. This month, we will be featuring 1. Community Support Group 2. Educational Workshop 3. Medical Support 4. Story Telling 5. SCD Clinic And many more. The above will be done this month and beyond. #sicklecellawareness #sicklecelldisease